Cherish
Lv54
830 积分
2025-03-26 加入
-
Understanding human mast cells: lesson from therapies for allergic and non-allergic diseases
2个月前
已完结
-
Predictive power of preclinical studies in animals for the immunogenicity of recombinant therapeutic proteins in humans
2个月前
已关闭
-
Abstract 5821: DXC008, a novel STEAP1 antibody-tubulysin analog conjugate with a function linker, demonstrates a potential to broaden therapeutic opportunities for prostate tumors
2个月前
已关闭
-
A Phase 1, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered SRSD107 in Healthy Subjects
2个月前
已关闭
-
SHR-2004, A Novel Humanised Monoclonal Antibody Targeting Factor XI (FXI), For Preventing Venous Thromboembolism (VTE) In Patients Undergoing Surgery For Ovarian Cancer: A Randomised, Active-Control Phase 2 Study
2个月前
已关闭
-
Rivaroxaban vs Dalteparin in Cancer-Associated Thromboembolism
2个月前
已完结
-
Extended Reduced-Dose Apixaban for Cancer-Associated Venous Thromboembolism
2个月前
已完结
-
SHR-2004, A Novel Humanised Monoclonal Antibody Targeting Factor XI (FXI), For Preventing Venous Thromboembolism (VTE) In Patients Undergoing Surgery For Ovarian Cancer: A Randomised, Active-Control Phase 2 Study
3个月前
已关闭
-
Will Factor XI Inhibitors Replace Current Anticoagulants for Stroke Prevention in Atrial Fibrillation?
3个月前
已完结
-
Asundexian versus Apixaban in Patients with Atrial Fibrillation
3个月前
已完结